Value Drug Company V. Takeda Pharmaceuticals, U.S.A, Inc., Et al, No. 21-cv03500) (E.D PA.)

Value Drug Company V. Takeda Pharmaceuticals, U.S.A, Inc., Et al, No. 21-cv03500) (E.D PA.)

Faruqi & Faruqi represents a proposed class of direct purchasers of Takeda Pharmaceuticals’ Colcrys, a prescription drug used for the treatment of Familial Mediterranean Fever and for the treatment and prevention of gout flares. The complaint alleges one or more conspiracies among Takeda, Par, Amneal, and Watson to unlawfully preserve Takeda’s Colcrys monopoly and to delay full generic competition.

Details
Filed On: August 5, 2021
Counsel
Joseph T. Lukens
jlukens@faruqilaw.com
Phone (215) 277-5770
Fax (215) 277-5771
Peter Kohn
pkohn@faruqilaw.com
Phone (215) 277-5770
Fax (215) 277-5771
Office
Pennsylvania
1617 JFK Boulevard, Suite 1550 Philadelphia Pennsylvania 19103
Phone (215) 277-5770
Fax (215) 277-5771

Our Offices

Our offices are nationwide. If you have any questions about a case or our firm, please contact us.
Send Us a Message
New York
685 Third Avenue 26th Floor
New York New York 10017
(877) 247-4292 / (212) 983-9330
(212) 983-9331
Los Angeles
1901 Avenue of the Stars Suite 1060
Los Angeles California 90067
(424) 256-2884
(424) 256-2885
Atlanta
3565 Piedmont Road NE Building Four, Suite 380
Atlanta Georgia 30305
(404) 847-0617
(404) 506-9534
Philadelphia
1617 JFK Boulevard, Suite 1550 Philadelphia
Pennsylvania 19103
(215) 277-5770
(215) 277-5771